Hulu's Handmaid's Tale spinoff finds 3rd lead
Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...
Oppenheimer raised the firm’s price target on Gilead (GILD) to $132 from $115 and keeps an Outperform rating on the shares. The firm says that ...
Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...
Gilead Sciences Inc. closed 0.11% below its 52-week high of $112.11, which the company reached on February 25th.
Analysts at RBC Capital Markets have predicted twice-yearly lenacapavir could become a $2 billion product, and become a key ...
Investors eyeing high-growth stocks should consider Corcept Therapeutics, TKO Group, and others with strong earnings ...
The Health and Human Services Department is reviewing contracts and moving to replace vaccine advisers in Robert F. Kennedy Jr.’s first few ...
19h
Hosted on MSNGilead Sciences (GILD) Rises As Market Takes a Dip: Key FactsIn the latest market close, Gilead Sciences (GILD) reached $115.99, with a +1.47% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 1.76%. Meanwhile, the Dow ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results